期刊文献+

自噬在糖皮质激素性骨质疏松症中的作用机制 被引量:4

Mechanism of autophagy in glucocorticoid-induced osteoporosis
下载PDF
导出
摘要 糖皮质激素性骨质疏松症(glucocorticoid-induced osteoporosis,GIOP)由长期或过量应用糖皮质激素(glucocorticoid,GC)所导致,其发病与骨质疏松症(osteoporosis,OP)相比有其自身特点。基于细胞自噬与OP的相关研究,探讨自噬与GC及GIOP三者之间的关联性。研究发现,在GC导致GIOP形成的过程中,针对不同GC浓度、不同细胞(BMSC、OB、骨细胞、OC)等,通过不同信号通路介导的细胞自噬发挥着复杂作用。要依据自噬对骨形成的积极作用开展GIOP的相关治疗,需要考虑多因素,将自噬水平精确调控在一个相对稳态范围内。 Glucocorticoid-induced osteoporosis(GIOP)caused by long-term or excessive use of glucocorticoid(GC)has its own characteristics in the disease development compared with osteoporosis(OP).Based on the research of autophagy and OP,the relationship between autophagy and GC and GIOP is discussed.In the process of GC induced GIOP formation,autophagy mediated by different signaling pathways plays a complex role in different GC concentrations and different cells(BMSC,OB,osteocytes,OC).In order to carry out the treatment of GIOP according to the positive effect of autophagy on bone formation,we need to consider multiple factors and accurately regulate the level of autophagy in a relatively stable range.
作者 张惜燕 胡勇 邢玉瑞 ZHANG Xiyan;HU Yong;XING Yurui(Shaanxi University of Chinese Medicine,Xianyang 712046,China)
机构地区 陕西中医药大学
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2022年第6期927-930,共4页 Chinese Journal of Osteoporosis
基金 陕西省教育厅重点科研计划项目(20JS029,19JS016) 陕西中医药大学学科创新团队项目(2019-YL01) 陕西省中医药管理局第二批中医药重点研究室建设项目(陕中医药发2018[32号]) 陕西省中医体质与疾病防治重点实验室(陕科基发[2012]1号)。
关键词 自噬 糖皮质激素 糖皮质激素性骨质疏松症 细胞 autophagy glucocorticoid glucocorticoid-induced osteoporosis cells
  • 相关文献

参考文献10

二级参考文献59

  • 1张维成.不同浓度地塞米松对骨髓基质细胞成脂、成骨分化的影响[J].中国临床康复,2006,10(29):98-100. 被引量:13
  • 2American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update[J].Arthritis Rheum,2001,44(7):1496-1503.
  • 3Reid DM,Devogelaer JP,Saag K,et al.Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON):a multicentre,double-blind,double-dummy,randomised controlled trial[J].Lancet,2009,373(9671):1253-1263.
  • 4van Staa TP,Geusens P,Pols HA,et al.A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids[J].QJM,2005,98(3):191-198.
  • 5Saag KG,Zanchetta JR,Devogelaer JP,et al.Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis:thirty-six-month results of a randomized,double-blind,controlled trial[J].Arthritis Rheum,2009,60(11):3346-3355.
  • 6Netelenbos JC,Geusens PP,Ypma G,et al.Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale,long-term retrospective study in The Netherlands[J].Osteoporos Int,2010,22 (5):1537-1546.
  • 7中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南.中国骨质疏松和骨矿物盐疾病杂志,2011,4: 2-17.
  • 8NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, andtherapy. JAMA, 2001,285: 785-795.
  • 9Compston JE. Management of glucocorticoid-induced osteoporosis,Nat Rev Rheumatol, 2010,6: 82-88.
  • 10Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Osteoporos, 1998, 27: 465-483.

共引文献104

同被引文献45

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部